Plant Heath Care (PHC ), a provider of patented biological products to global agriculture markets, updated markets this morning on volume production of its Harpin αβ-based portfolio. Harpin αβ is a natural method of activating a plant's defense systems, similar to a vaccine that makes plants more resilient and improves yields. Harpin αβ is the active ingredient in the company's ProAct, Employ, and H2Copla products.
Plant Heath Care reported it has entered into a supply agreement with a European fermentation company, enabling at-scale production of Harpin αβ. The move to the new high-capacity facility will enable the Company to meet current and future volume manufacture cost targets through better economies of scale and eliminating certain import costs. The move will unlock improved gross margins and higher ROI for Plant Health Care's clients.
Plant Health Care also announced it would manufacture PREtec peptides in the same facility with a goal of launching a new category of PREtec-based products, pending regulatory filings. PREtec is a protein-based biotechnology that stimulates a plant to defend itself. It is a natural and environmentally friendly method of protecting crops from pests and diseases.
Jeff Tweedy, COO, commented: "I am pleased to move our product manufacturing to a high-quality facility in Europe that has both the experience and capacity to meet our current product volume requirements as well as projected future increased demand for our Harpin αβ products and the PREtec product portfolio, including Saori®. By eliminating the need to pay certain import tariffs and other costs, gross margin is expected to improve for our Harpin αβ business beginning in 2023."
Follow News & Updates from Plant Health Care: